开设账户
模拟账户
关于我们
即时报价及新闻
市场分析
财经日历
每日市场分析
交易平台
下载及介绍
使用教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
繁
简
EN
客户登入
开设账户
模拟账户
繁
简
EN
客户登入
开设账户
模拟账户
关于我们
上志国际介绍
上志国际优势
即时报价及新闻
即时报价
即时新闻
市场分析
财经日历
市场分析
交易平台
平台特点
平台教学
交易细则
各项细则
资金提存
推广和资讯
常见问题
联络我们
关于我们
交易细则
贵金属市场
交易平台
市场分析
推广和资讯
常见问题
联络我们
繁
简
EN
巴西财政部长杜里甘:301条款调查更具政治性而非技术性。
2026-06-01
巴西财政部长杜里甘:301条款调查更具政治性而非技术性。
返回
其他消息
2026-06-01
China's Shanghai Composite fell 0.12% at the mid-day close after earlier gains; the Shenzhen Composite dropped 0.60% and the ChiNext index fell 0.90%. AI PC-theme names were active, with Huaqin Technology among several stocks hitting daily limit-up. Coal, chemicals and power-grid equipment sectors strengthened, also seeing multiple limit-up moves. CPO and PCB themes weakened, with Cambridge Technology at the daily limit-down. AI application, sports and oil & gas sectors were among the top perfor
China's Shanghai Composite fell 0.12% at the mid-day close after earlier gains; the Shenzhen Composite dropped 0.60% and the ChiNext index fell 0.90%. AI PC-theme names were active, with Huaqin Technology among several stocks hitting daily limit-up. Coal, chemicals and power-grid equipment sectors strengthened, also seeing multiple limit-up moves. CPO and PCB themes weakened, with Cambridge Technology at the daily limit-down. AI application, sports and oil & gas sectors were among the top performers; glass/fibreglass, semiconductors and baijiu lagged. Market breadth skewed positive, with more than 3,800 A-shares rising.
2026-06-01
Haisco said its self-developed Class 1 innovative intravenous anesthetic, ciprofol injection, has received US FDA approval for induction of general anesthesia in adults. Ciprofol is the first China-originated original intravenous anesthetic to secure international market approval.
Haisco said its self-developed Class 1 innovative intravenous anesthetic, ciprofol injection, has received US FDA approval for induction of general anesthesia in adults. Ciprofol is the first China-originated original intravenous anesthetic to secure international market approval.
Chat with us
, powered by
LiveChat